外周血可溶性CD44v6测定用于侵袭性垂体腺瘤辅助性诊断

Measurement of Soluble CD44v6 in Periheral Blood as Assistant Diagnosis of Invasive Pituitary Adenomas

目的探讨测定外周血可溶性细胞粘附分子CD44变异体6sCD44v6)含量对侵袭性和非侵袭性垂体腺瘤诊断的价值。方法酶联免疫吸附法测定68例侵袭性垂体腺瘤和100例非侵袭性垂体腺瘤患者外周血sCD44v6的含量。结果侵袭性垂体微腺瘤、大腺瘤和巨大腺瘤患者血清sCD44v6含量分别为44.63±7.21、(34.53±6.41)和(26.34±4.95)ng/ml,非侵袭性垂体微腺瘤、大腺瘤和巨大腺瘤患者分别为60.78±9.61、(57.78±10.00)和(37.22±5.17)ng/ml,均较对照组(68.73±6.00)ng/ml低(P<0.05)。侵袭性垂体微腺瘤、大腺瘤、巨大腺瘤患者外周血sCD44v6含量均较对应的非侵袭性垂体微腺瘤、大腺瘤、巨大腺瘤患者降低,组间差异具有显著意义(P<0.005)。外周血sCD44v6含量随着肿瘤体积增大而降低(P<0.01),尤以侵袭性垂体腺瘤显著,其诊断侵袭性垂体腺瘤符合率达89.71%。结论外周血sCD44v6含量与垂体腺瘤大小和侵袭性生长行为呈负相关,可能对侵袭性垂体大腺瘤、巨大腺瘤的诊断、治疗决策和判断预后具有一定的参考价值。

To investigate the value of measuring the concentration of soluble CD44 splice variant 6(sCD44v6)in peripheral blood in patients with invasive and non-invasive pituitary adenomas. Methods The concentrations of sCD44v6 in peripheral blood were measured with ELISA in 68 patients with invasive pituitary adenomas and 100 patients with non-invasive pituitary adenomas. Results The serum concentration of sCD44v6 in patients with invasive pituitary adenomas was lower than that in patients with non-invasive pituitary adenomas, while the latter was lower than that in healthy controls. The serum concentrations of sCD44v6 were(44.63 ± 7.21),(34.53 ± 6.41), and (26.34 ± 4.95)ng/ml in patients with invasive microadenoma, macroadenoma, and giant adenoma, and (60.78 ± 9.61),(57.78 ± 10.00), and(37.22 ± 5.17)ng/ml in patients with non-invasive microadenoma, macroadenoma, and giant adenoma, lower than that in the healthy control group(68.73 ± 6.00)ng/ml. Significant differences were observed among groups(P < 0.005). The concentration of sCD44v6 in peripheral blood decreased as the tumor size increased(P < 0.01), which was particularly significant in invasive pituitary adenomas. The positive rate in the patients with invasive pituitary adenomas reached 89.71%. Conclusion Serum concentration of sCD44v6 in the peripheral blood is inversely correlated with tumor size and its invasive growth, which may provide certain value in the early diagnosis, treatment and prognosis of invasive pituitary macroadenoma and giant adenoma.